Nasdaq Issues Delisting Warning to Aimei Health Over Delayed Annual Report
AFJK has more than doubled off its 52-week low of $6.75 on light trading volume (0.3× avg).
Summary
Aimei Health Technology Co., Ltd. (AFJK) has received a Nasdaq deficiency notice for failing to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This follows the company's notification of late filing on April 1, 2026, and an 8-K filing on April 7th, which likely reported the initial delay. The notice indicates non-compliance with Nasdaq's listing rules and puts the company at risk of delisting if it fails to regain compliance. While the company states it is working diligently to file the report and expects to comply, this raises concerns about its financial reporting and corporate governance, which is critical for a blank check company. Investors will be watching for the timely filing of the 10-K within the 60-day period or the acceptance of a compliance plan.
At the time of this announcement, AFJK was trading at $41.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $249.8M. The 52-week trading range was $6.75 to $130.37. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.